Literature DB >> 23144579

Chemotherapy uptake and wait times in early-stage non-small-cell lung cancer.

S Gray1, J Bu, N Saint-Jacques, D Rayson, T Younis.   

Abstract

BACKGROUND: Treatment uptake and elapsed times along the care path have emerged as potential quality indicators for cancer care delivery. This retrospective study examined changes in adjuvant chemotherapy uptake and elapsed times along the care path for patients in 2005 and in 2007 who had early-stage non-small-cell lung cancer (nsclc) and who underwent curative-intent surgery in Nova Scotia, Canada.
METHODS: All patients who underwent curative-intent surgery for stages i-iii nsclc in the two years of interest were included. Logistic regression and general linear models were used to examine factors associated with chemotherapy uptake patterns and, at various resolutions (low, intermediate, high), elapsed times between all care events in the care path.
RESULTS: In the 223 patients who underwent curative-intent surgery (108 in 2005, 115 in 2007), several factors were associated with uptake patterns and elapsed times. Cohort year (2007 vs. 2005) was not associated with referral to medical oncology [odds ratio (or): 1.05; 95% confidence interval (ci): 0.51 to 2.15; p = 0.905], but it was associated with less treatment after referral (or: 0.34; 95% ci: 0.11 to 1.00; p = 0.057) and less overall uptake (or: 0.35; 95% ci: 0.13 to 0.95; p = 0.040). Patients were referred sooner to medical oncology in 2007 than in 2005 (21 days vs. 35 days, p = 0.008), but experienced longer waits between consultation and chemotherapy delivery (18 days vs. 7 days, p = 0.001).
CONCLUSIONS: Significant differences were observed in care patterns over time. Frequent monitoring of care patterns at high resolution may optimize insights into emerging trends within cancer care systems.

Entities:  

Keywords:  Non-small-cell lung cancer; adjuvant chemotherapy; elapsed times; treatment uptake; wait times

Year:  2012        PMID: 23144579      PMCID: PMC3457882          DOI: 10.3747/co.19.1020

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  22 in total

1.  Waiting for medical services in Canada: lots of heat, but little light.

Authors:  C Sanmartin; S E Shortt; M L Barer; S Sheps; S Lewis; P W McDonald
Journal:  CMAJ       Date:  2000-05-02       Impact factor: 8.262

2.  Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials.

Authors:  Katsuyuki Hotta; Keitaro Matsuo; Hiroshi Ueoka; Katsuyuki Kiura; Masahiro Tabata; Mitsune Tanimoto
Journal:  J Clin Oncol       Date:  2004-08-23       Impact factor: 44.544

3.  Adoption of adjuvant chemotherapy for non-small-cell lung cancer: a population-based outcomes study.

Authors:  Christopher M Booth; Frances A Shepherd; Yingwei Peng; Gail E Darling; Gavin Li; Weidong Kong; William J Mackillop
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 44.544

4.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

Authors:  Timothy Winton; Robert Livingston; David Johnson; James Rigas; Michael Johnston; Charles Butts; Yvon Cormier; Glenwood Goss; Richard Inculet; Eric Vallieres; Willard Fry; Drew Bethune; Joseph Ayoub; Keyue Ding; Lesley Seymour; Barbara Graham; Ming-Sound Tsao; David Gandara; Kenneth Kesler; Todd Demmy; Frances Shepherd
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

5.  Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

Authors:  Giorgio V Scagliotti; Roldano Fossati; Valter Torri; Lucio Crinò; Giuseppe Giaccone; Giovanni Silvano; Massimo Martelli; Maurizia Clerici; Francesco Cognetti; Maurizio Tonato
Journal:  J Natl Cancer Inst       Date:  2003-10-01       Impact factor: 13.506

6.  Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.

Authors:  Katherine M W Pisters; William K Evans; Christopher G Azzoli; Mark G Kris; Christopher A Smith; Christopher E Desch; Mark R Somerfield; Melissa C Brouwers; Gail Darling; Peter M Ellis; Laurie E Gaspar; Harvey I Pass; David R Spigel; John R Strawn; Yee C Ung; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

7.  Waiting times in early-stage non-small cell lung cancer (NSCLC).

Authors:  Nathalie Saint-Jacques; Daniel Rayson; Turki Al-Fayea; Kiran Virik; Wojciech Morzycki; Tallal Younis
Journal:  J Thorac Oncol       Date:  2008-08       Impact factor: 15.609

8.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.

Authors:  Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway.

Authors:  N R Lewis; I Le Jeune; D R Baldwin
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

10.  Variation in the use of chemotherapy in lung cancer.

Authors:  N Patel; R Adatia; A Mellemgaard; R Jack; H Møller
Journal:  Br J Cancer       Date:  2007-03-06       Impact factor: 7.640

View more
  2 in total

1.  Factors associated with receipt of symptom screening in the year after cancer diagnosis in a universal health care system: a retrospective cohort study.

Authors:  A L Mahar; L E Davis; L D Bubis; Q Li; R Sutradhar; N G Coburn; L Barbera
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  Transfer between hospitals as a predictor of delay in diagnosis and treatment of patients with Non-Small Cell Lung Cancer - a register based cohort-study.

Authors:  Maria Iachina; Erik Jakobsen; Anne Kudsk Fallesen; Anders Green
Journal:  BMC Health Serv Res       Date:  2017-04-12       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.